ADC Approval Likely to Spur More Research
- PMID: 28851687
- DOI: 10.1158/2159-8290.CD-NB2017-120
ADC Approval Likely to Spur More Research
Abstract
The FDA's decision to approve inotuzumab ozogamicin for patients with relapsed or refractory acute lymphoblastic leukemia could open up further uses for the drug. It is being tested as a first-line treatment in combination with chemotherapy. The decision could also stimulate research into other antibody-drug conjugates.
©2017 American Association for Cancer Research.
Comment on
-
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12. N Engl J Med. 2016. PMID: 27292104 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
